GRI Bio (GRI) Interest & Investment Income (2021 - 2022)
GRI Bio (GRI) posted quarterly Interest & Investment Income of $3000.0 for Q2 2022, up 175.0% quarter-over-quarter from -$4000.0 in Q1 2022.
GRI Bio (GRI) Interest & Investment Income (2021 - 2022) Analysis & Trends
GRI Bio's Interest & Investment Income history runs 2 years deep, the most recent figure standing at $3000.0 for Q2 2022.
- In Q2 2022, Interest & Investment Income changed N/A year-over-year to $3000.0; the TTM figure through Mar 2023 stood at -$2000.0 (up 66.67% YoY), while the FY2022 annual figure was $2000.0, up 200.0% from the prior year.
- Interest & Investment Income for Q2 2022 stood at $3000.0, up from -$4000.0 in the prior quarter.
- The five-year high for Interest & Investment Income was $3000.0 in Q2 2022, with the low at -$4000.0 in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 120.60 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | -48.00 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 48.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 67.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 27.90 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 28.14 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 115.94 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 10.98 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 5.13 Mn |
| 10 | GRI Bio | 3.01 Mn | 3.01 Mn | - | 5,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2022 | 3,000.00 |
| Mar 31, 2022 | -4,000.00 |
| Dec 31, 2021 | -1,000.00 |
| Sep 30, 2021 | -1,000.00 |